Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
Not Confirmed
Not Confirmed
11-14 November, 2024
TIDES Europe 2024TIDES Europe 2024
Not Confirmed
Not Confirmed
12-14 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
Industry Trade Show
Not Confirmed
11-14 November, 2024
TIDES Europe 2024TIDES Europe 2024
Industry Trade Show
Not Confirmed
12-14 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/medical-breakthroughs-in-2024-alzheimer-s-schizophrenia-copd-mash-see-pathbreaking-treatments
12 Nov 2024
// BUSINESSWIRE
05 Nov 2024
// BUSINESSWIRE
28 Oct 2024
// BUSINESSWIRE
18 Oct 2024
// BUSINESSWIRE
04 Oct 2024
// BUSINESSWIRE
02 Oct 2024
// BUSINESSWIRE
Details:
KVD900 (sebetralstat) is an investigational novel, oral plasma kallikrein inhibitor, which is being developed for the treatment of hereditary angioedema in patients aged 2 to 11 years.
Lead Product(s): Sebetralstat
Therapeutic Area: Genetic Disease Brand Name: KVD900
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2024
Lead Product(s) : Sebetralstat
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
KalVista Submits MAAs For Sebetralstat For Hereditary Angioedema
Details : KVD900 (sebetralstat) is an investigational novel, oral plasma kallikrein inhibitor, which is being developed for the treatment of hereditary angioedema in patients aged 2 to 11 years.
Brand Name : KVD900
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 30, 2024
Details:
KVD900 (sebetralstat) is an investigational novel, oral plasma kallikrein inhibitor, which is being developed for the treatment of hereditary angioedema in patients aged 2 to 11 years.
Lead Product(s): Sebetralstat
Therapeutic Area: Genetic Disease Brand Name: KVD900
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 03, 2024
Lead Product(s) : Sebetralstat
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
KalVista Secures FDA Approval of NDA for Sebetralstat in Hereditary Angioedema
Details : KVD900 (sebetralstat) is an investigational novel, oral plasma kallikrein inhibitor, which is being developed for the treatment of hereditary angioedema in patients aged 2 to 11 years.
Brand Name : KVD900
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 03, 2024
Details:
KVD900 (sebetralstat) is an investigational novel, oral plasma kallikrein inhibitor, which is being developed for the treatment of hereditary angioedema in patients aged 2 to 11 years.
Lead Product(s): Sebetralstat
Therapeutic Area: Genetic Disease Brand Name: KVD900
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2024
Lead Product(s) : Sebetralstat
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
KalVista Initiates KONFIDENT-KID Trial for Sebetralstat in Children with Angioedema
Details : KVD900 (sebetralstat) is an investigational novel, oral plasma kallikrein inhibitor, which is being developed for the treatment of hereditary angioedema in patients aged 2 to 11 years.
Brand Name : KVD900
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 27, 2024
Details:
KVD900 (sebetralstat) is an investigational novel, oral plasma kallikrein inhibitor, which is being developed for the treatment of hereditary angioedema in patients aged 12 years & older.
Lead Product(s): Sebetralstat
Therapeutic Area: Genetic Disease Brand Name: KVD900
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 18, 2024
Lead Product(s) : Sebetralstat
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
KalVista Submits NDA for Sebetralstat for Hereditary Angioedema
Details : KVD900 (sebetralstat) is an investigational novel, oral plasma kallikrein inhibitor, which is being developed for the treatment of hereditary angioedema in patients aged 12 years & older.
Brand Name : KVD900
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 18, 2024
Details:
KVD900 (sebetralstat) is an investigational novel, oral plasma kallikrein inhibitor, which is being developed for the treatment of hereditary angioedema.
Lead Product(s): Sebetralstat
Therapeutic Area: Genetic Disease Brand Name: KVD900
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 12, 2024
Lead Product(s) : Sebetralstat
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
KalVista Pharmaceuticals Awarded UK PIM Designation for Sebetralstat
Details : KVD900 (sebetralstat) is an investigational novel, oral plasma kallikrein inhibitor, which is being developed for the treatment of hereditary angioedema.
Brand Name : KVD900
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 12, 2024
Details:
The proceeds will support clinical trials and product development of KVD900 (sebetralstat), a plasma kallikrein inhibitor for hereditary angioedema.
Lead Product(s): Sebetralstat
Therapeutic Area: Genetic Disease Brand Name: KVD900
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Jefferies
Deal Size: $160.1 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 15, 2024
Lead Product(s) : Sebetralstat
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Jefferies
Deal Size : $160.1 million
Deal Type : Public Offering
KalVista Pharmaceuticals Prices $160.1 Million Public Offering
Details : The proceeds will support clinical trials and product development of KVD900 (sebetralstat), a plasma kallikrein inhibitor for hereditary angioedema.
Brand Name : KVD900
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 15, 2024
Details:
The net proceeds will be used for the clinical development of KVD900 (sebetraslat), which is an oral plasma kallikrein inhibitor used for the treatment of hereditary angioedema.
Lead Product(s): Sebetralstat
Therapeutic Area: Genetic Disease Brand Name: KVD900
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Jefferies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering February 14, 2024
Lead Product(s) : Sebetralstat
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Jefferies
Deal Size : Undisclosed
Deal Type : Public Offering
KalVista Pharmaceuticals Proposes Public Offering of Common Stock and Pre-Funded Warrants
Details : The net proceeds will be used for the clinical development of KVD900 (sebetraslat), which is an oral plasma kallikrein inhibitor used for the treatment of hereditary angioedema.
Brand Name : KVD900
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 14, 2024
Details:
KVD900 (sebetralstat) is an investigational novel, oral plasma kallikrein inhibitor, which is being developed for the treatment of hereditary angioedema.
Lead Product(s): Sebetralstat
Therapeutic Area: Genetic Disease Brand Name: KVD900
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2024
Lead Product(s) : Sebetralstat
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
KalVista Reports Phase 3 KONFIDENT Trial Meets Endpoints for Sebetralstat in Angioedema
Details : KVD900 (sebetralstat) is an investigational novel, oral plasma kallikrein inhibitor, which is being developed for the treatment of hereditary angioedema.
Brand Name : KVD900
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 13, 2024
Details:
KVD900 (sebetralstat) is an oral plasma kallikrein inhibitor and the most advanced compound in our portfolio of candidates for the treatment of hereditary angioedema (HAE).
Lead Product(s): Sebetralstat
Therapeutic Area: Genetic Disease Brand Name: KVD900
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2023
Lead Product(s) : Sebetralstat
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
KalVista Pharmaceuticals Announces Phase 3 KONFIDENT Trial Milestone Achieved
Details : KVD900 (sebetralstat) is an oral plasma kallikrein inhibitor and the most advanced compound in our portfolio of candidates for the treatment of hereditary angioedema (HAE).
Brand Name : KVD900
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 13, 2023
Details:
KVD900 (sebetralstat) is an oral plasma kallikrein inhibitor and the most advanced compound in our portfolio of candidates for the treatment of hereditary angioedema (HAE).
Lead Product(s): Sebetralstat
Therapeutic Area: Genetic Disease Brand Name: KVD900
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2023
Lead Product(s) : Sebetralstat
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
KalVista Pharmaceuticals Provides Progress Updates on Sebetralstat Development
Details : KVD900 (sebetralstat) is an oral plasma kallikrein inhibitor and the most advanced compound in our portfolio of candidates for the treatment of hereditary angioedema (HAE).
Brand Name : KVD900
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 14, 2023
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?